Tags

Type your tag names separated by a space and hit enter

[Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Zhonghua Xue Ye Xue Za Zhi. 2003 Aug; 24(8):416-9.ZX

Abstract

OBJECTIVE

To explore the feasibility of a new protocol for acute graft versus host disease (aGVHD) prophylaxis in haploidentical bone marrow transplantation.

METHODS

Thirty-eight high-risk leukemia patients underwent haploidentical G-CSF primed bone marrow transplantation without ex-vivo T cell depletion, the donors were given G-CSF 250 microg/d for 7 days prior to marrow harvest. All patients received a same chemo-radiation conditioning regimen, including cytarabin, cyclophosphamide and total body irradiation (TBI). GVHD prophylaxis regimen consisted of ATG, CsA, MTX, Mycophenolate mofetil (MMF) and anti-CD(25) monoclonal antibody (MoAb).

RESULTS

All patients achieved engraftment of a median of 19 and 22 days for neutrophil and platelet, respectively. Cytogenetic analysis showed 100% donor hematopoietic cells in all recipients after transplantation. One of the twenty patients (5%) experienced grades II - IV acute GVHD. The recovery of CD(3)(+)CD(8)(+) T cells, CD(19)(+) cells and CD(56)(+) cells after transplantation was within 3 approximately 12 months. Of the 20 patients, 16 were alive with minimal and limited chronic GVHD and karnofsky score over 90% in a median follow-up of 9 months. Disease free survival (DFS) rates was (80 +/- 9)%.

CONCLUSION

G-CSF priming marrow graft along with sequential immunosuppressants, especially the addition of anti-CD(25) MoAb for aGVHD prophylaxis could achieve excellent engraftment, proper immune reconstitution and very low incidence of grade II - IV GVHD. The new protocol is effective and feasible in preventing severe acute GVHD and improving DFS.

Authors+Show Affiliations

Department of Hematology, The General Hospital of Air Force PLA, Beijing 100036, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

14642179

Citation

Ji, Shu-quan, et al. "[Clinical Study of a New Protocol for Acute Graft-versus Host Disease Prophylaxis in HLA-haploidentical Bone Marrow Transplantation (BMT)]." Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 24, no. 8, 2003, pp. 416-9.
Ji SQ, Chen HR, Wang HX, et al. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)]. Zhonghua Xue Ye Xue Za Zhi. 2003;24(8):416-9.
Ji, S. Q., Chen, H. R., Wang, H. X., Yan, H. M., Liu, J., Xue, M., & Zhu, L. (2003). [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 24(8), 416-9.
Ji SQ, et al. [Clinical Study of a New Protocol for Acute Graft-versus Host Disease Prophylaxis in HLA-haploidentical Bone Marrow Transplantation (BMT)]. Zhonghua Xue Ye Xue Za Zhi. 2003;24(8):416-9. PubMed PMID: 14642179.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)]. AU - Ji,Shu-quan, AU - Chen,Hui-ren, AU - Wang,Heng-xiang, AU - Yan,Hong-min, AU - Liu,Jing, AU - Xue,Mei, AU - Zhu,Ling, PY - 2003/12/4/pubmed PY - 2007/5/23/medline PY - 2003/12/4/entrez SP - 416 EP - 9 JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JO - Zhonghua Xue Ye Xue Za Zhi VL - 24 IS - 8 N2 - OBJECTIVE: To explore the feasibility of a new protocol for acute graft versus host disease (aGVHD) prophylaxis in haploidentical bone marrow transplantation. METHODS: Thirty-eight high-risk leukemia patients underwent haploidentical G-CSF primed bone marrow transplantation without ex-vivo T cell depletion, the donors were given G-CSF 250 microg/d for 7 days prior to marrow harvest. All patients received a same chemo-radiation conditioning regimen, including cytarabin, cyclophosphamide and total body irradiation (TBI). GVHD prophylaxis regimen consisted of ATG, CsA, MTX, Mycophenolate mofetil (MMF) and anti-CD(25) monoclonal antibody (MoAb). RESULTS: All patients achieved engraftment of a median of 19 and 22 days for neutrophil and platelet, respectively. Cytogenetic analysis showed 100% donor hematopoietic cells in all recipients after transplantation. One of the twenty patients (5%) experienced grades II - IV acute GVHD. The recovery of CD(3)(+)CD(8)(+) T cells, CD(19)(+) cells and CD(56)(+) cells after transplantation was within 3 approximately 12 months. Of the 20 patients, 16 were alive with minimal and limited chronic GVHD and karnofsky score over 90% in a median follow-up of 9 months. Disease free survival (DFS) rates was (80 +/- 9)%. CONCLUSION: G-CSF priming marrow graft along with sequential immunosuppressants, especially the addition of anti-CD(25) MoAb for aGVHD prophylaxis could achieve excellent engraftment, proper immune reconstitution and very low incidence of grade II - IV GVHD. The new protocol is effective and feasible in preventing severe acute GVHD and improving DFS. SN - 0253-2727 UR - https://www.unboundmedicine.com/medline/citation/14642179/[Clinical_study_of_a_new_protocol_for_acute_graft_versus_host_disease_prophylaxis_in_HLA_haploidentical_bone_marrow_transplantation__BMT_]_ L2 - http://www.diseaseinfosearch.org/result/7171 DB - PRIME DP - Unbound Medicine ER -